Monoclonal antibodies which specifically bind human CD23, the low affinity
receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3
constant domain, are disclosed. The antibodies are useful for modulating or inhibiting
induced IgE expression. Accordingly, they have practical utility in the treatment
or prophylaxis of disease conditions wherein inhibition of induced IgE production
is therapeutically desirable, including allergic conditions, autoimmune diseases
and inflammatory diseases.
